BioVie and BioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
BioVie and BioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / July 5, 2024 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small Stocks, Big Money show, a sponsored program on Bloomberg TV, this Saturday, July 6, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
RedChip公司将在Bloomberg电视上赞助的节目《RedChip节目》于东部时间7月6日星期六晚7点播出BioVie, Inc. (纳斯达克:BIVI)和bioAffinity Technologies, Inc. (纳斯达克:BIAF)的采访。Bloomberg TV 可通过大约7300万美国家庭观看。小公司股票、大钞票bioAffinity Technologies:
Access the interviews in their entirety at:
Soligenix:
BioVie:
bioAffinity Technologies:
BioVie：
bioAffinity Technologies的总裁兼首席执行官Maria Zannes将在Bloomberg TV的RedChip节目上提供公司更新。bioAffinity Technologies是早期癌症诊断领域的新兴参与者。其旗舰产品CyPath Lung通过分析肺部微环境提高早期肺癌的检测效率。这种非侵入性的测试具有高灵敏度、特异性和准确性。肺癌往往在达到晚期时才被发现，治疗方案的效果不佳。早期检测可提高生存率并降低医疗费用。随着商业化计划的推广，包括德克萨斯州的试点计划和美国国防部为进行持续性研究而购买测试，公司已为创业板做好了准备。到2030年，肺癌筛查市场预计将达到57亿美元。公司正在开发由人工智能驱动的自动化数据分析来协助非侵入性诊断慢性阻塞性肺疾病和哮喘的细胞流式分析平台，这两种疾病的全球市场预计将在2027年达到82亿美元。公司拥有广泛的美国和国际专利。内部人士对公司的持股力度非常强，持股比例为39%并且持续增加。拥有高度经验的领导团队，bioAffinity Technologies在早期癌症诊断领域具备推动创新的优势。
In an exclusive interview, Cuong Do, President and CEO of BioVie, who will share insight into the Company's pipeline of late-stage clinical programs targeting unmet medical needs in neurodegeneration and liver disease. BioVie's lead asset, bezisterim (formerly NE3107), has demonstrated the ability to modulate TNFα production, leading to significant clinical improvements. Patients treated with bezisterim experienced reduced inflammation and insulin resistance, improved motor control and "morning on" symptoms in Parkinson's disease (PD), enhanced cognition and function, and better brain imaging scans in Alzheimer's disease (AD), as well as reduced DNA methylation levels. The Company's strategic priorities include launching a Phase 2b trial for Parkinson's in Fall 2024, initiating a Phase 3 trial for Alzheimer's in mid-2025 with a new once-daily formulation of bezisterim, continuing partnering discussions for bezisterim's geographic rights, and commencing an ascites Phase 3 trial upon identifying a suitable partner.
在一次独家采访中，BioVie的总裁兼首席执行官Cuong Do将分享有关公司针对神经退行性和肝病等未满足医学需求的晚期临床项目管道的见解。BioVie的主要资产bezisterim（前NE3107）已经证明其调节TNFα的产生能力，从而带来了重大的临床改善。接受bezisterim治疗的患者经历了气体降低和胰岛素抵抗，改善了帕金森氏症（PD）运动控制和“晨起症状”，提高了认知和功能，并在阿尔茨海默病（AD）方面改善了脑成像扫描，以及降低了DNA的甲基化水平。该公司的战略重点包括在2024年秋季启动针对帕金森病的二期试验，在2025年中期启动使用新的一天一次的制剂的阿尔茨海默病三期试验bezisterim，持续寻找bezisterim地理权益的合作伙伴，并在确定合适的合作伙伴后启动一项腹水三期试验。
Maria Zannes, President and CEO of bioAffinity Technologies, appears on the RedChip Small Stocks, Big Money show on Bloomberg TV to provide a corporate update. bioAffinity Technologies is an emerging player in early-stage cancer diagnosis. Its flagship product, CyPath Lung, improves detection of early-stage lung cancer by analyzing the lung microenvironment. The noninvasive test has shown high sensitivity, specificity and accuracy. Lung cancer often goes undetected until it reaches late-stage when treatment options are less effective. Early detection increases survival and reduces medical costs. With commercialization underway, including a pilot program in Texas and the US DoD's purchase of tests for ongoing research, the Company is well-poised for growth. The lung cancer screening market is projected to reach $5.7 billion by 2030. The Company's flow cytometry platform, enhanced by AI-driven automated data analysis, is being developed to aid in noninvasive diagnosis of COPD and asthma, which have a combined global market expected to reach $8.2 billion by 2027. The Company holds extensive U.S. and international patents. Insiders show strong support for the Company with ownership at 39% and increasing. With a highly experienced leadership team, bioAffinity Technologies is well-positioned to drive innovation in early-stage cancer diagnosis.
bioAffinity Technologies的总裁兼首席执行官Maria Zannes将在Bloomberg电视台的RedChip节目上亮相，提供公司更新。小公司股票、大钞票bioAffinity Technologies是早期癌症诊断领域的新兴参与者。其旗舰产品CyPath Lung通过分析肺部微环境提高早期肺癌的检测效率。这种非侵入性的测试具有高灵敏度、特异性和准确性。肺癌往往在达到晚期时才被发现，治疗方案的效果不佳。早期检测可提高生存率并降低医疗费用。随着商业化计划的推广，包括德克萨斯州的试点计划和美国国防部为进行持续性研究而购买测试，公司已为创业板做好了准备。到2030年，肺癌筛查市场预计将达到57亿美元。公司正在开发由人工智能驱动的自动化数据分析来协助非侵入性诊断慢性阻塞性肺疾病和哮喘的细胞流式分析平台，这两种疾病的全球市场预计将在2027年达到82亿美元。公司拥有广泛的美国和国际专利。内部人士对公司的持股力度非常强，持股比例为39%并且持续增加。拥有高度经验的领导团队，bioAffinity Technologies在早期癌症诊断领域具备推动创新的优势。
About BioVie Inc.
BioVie股份有限公司（NASDAQ：BIVI）是一家临床阶段公司，致力于开发治疗神经系统和神经退行性疾病以及先进肝病的创新药物疗法。
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of ERK and NFκB (e.g., TNF signaling) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both are drivers of AD and PD. In liver disease, the Company's Orphan drug candidate BIV201 (continuous infusion terlipressin), with U.S. Food and Drug Administration ("FDA") Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the treatment of ascites due to chronic liver cirrhosis. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit .
BioVie Inc. (NASDAQ: BIVI)是一家国内处于临床阶段的公司，致力于研发针对神经和神经退行性疾病以及先进肝病的创新药物疗法。在神经退行性疾病中，公司的药物候选bezisterim抑制ERK和NFκB（例如，TNF信号转导）的炎症活化，导致神经炎症和胰岛素抵抗，但不影响它们的稳态功能（例如，胰岛素信号转导和神经元生长和存活）。都是阿尔茨海默病（AD）和帕金森氏症（PD）的驱动因素。在肝病方面，公司的孤儿药物候选BIV201（连续输注替利福汀），经美国食品和药品管理局（“FDA”）加速审批，正在评估中，并已收到FDA关于对由慢性肝硬化引起的腹水进行BIV201三期临床测试设计的指导。这种活性物质在美国和大约40个国家中被批准用于治疗晚期肝硬化的相关并发症。有关更多信息，请访问。
About bioAffinity Technologies, Inc.
关于bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. The Company's first product, CyPathLung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPathLung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. Research and optimization of the Company's platform technologies are conducted in its laboratories at Precision Pathology and The University of Texas at San Antonio. For more information, visit and follow us on LinkedIn, Facebook and X.
bioAffinity Technologies, Inc.致力于非侵入性诊断早期癌症和肺部疾病以及广谱抗癌治疗的需要。该公司的第一个产品CyPath Lung是一种非侵入性的测试，已经显示出检测早期肺癌的高灵敏度、特异性和准确性。CyPath Lung是BioAffinity Technologies子公司Precision Pathology实验室开发的一种实验室开发的测试。公司在Precision Pathology和The University of Texas at San Antonio的实验室中开展了平台技术的研究和优化。欲了解更多信息，请登陆官方网站，并在LinkedIn、Facebook和X上关注我们。Lung是一种非侵入性的测试，已经显示出检测早期肺癌的高灵敏度、特异性和准确性。CyPath Lung是由BioAffinity Technologies子公司Precision Pathology实验室开发的一种实验室开发的测试。
About RedChip Companies
关于RedChip公司
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 32 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
RedChip公司是一家国际投资者关系、媒体和研究公司，是一家美国《Inc.》杂志5000强公司，专注于微型市值和小市值公司。32年来，RedChip为客户提供了具体、可衡量的成果。我们的新闻简报，“小公司股票、大钞票”，每周在线上向6万投资者发送。RedChip已经开发出行业中最全面的服务平台，为微型市值和小市值公司提供以下服务：股票研究的全球分销网络；在美国主要城市进行散户和机构路演；外发营销给股票经纪人、RIA、机构和家族办公室；数字媒体投资者关系平台，为股东带来数百万次独特的投资者浏览量；投资者网络研讨会和集体电话；电视节目，“小公司股票、大钞票”，每周在Bloomberg US播出；在地方和全国市场上的电视广告；公司和产品视频；网站设计；传统投资者关系服务，包括新闻稿撰写、投资者演示文稿的制作、季度电话会议剧本的编写、战略咨询、融资等。小公司股票、大钞票在线向6万投资者每周发送的电子邮件新闻简报，“小公司股票、大钞票”小公司股票、大钞票在Bloomberg US每周播出的电视节目“小公司股票、大钞票”
To learn more about RedChip's products and services, please visit:
要了解更多有关RedChip的产品和服务的信息，请访问：
"Discovering Tomorrow's Blue Chips Today"
“发现明日的蓝筹股”
Follow RedChip on LinkedIn:
在LinkedIn上关注RedChip：
Follow RedChip on Facebook:
在Facebook上关注RedChip：
Follow RedChip on Instagram:
在Instagram上关注RedChip：
Follow RedChip on Twitter:
在Twitter上关注RedChip：
Follow RedChip on YouTube:
在YouTube上关注RedChip：
Follow RedChip on Rumble:
在Rumble上关注RedChip：
Subscribe to our Mailing List:
订阅我们的邮件列表：
Contact:
联系方式：
Dave Gentry
RedChip Companies Inc.
1-407-644-4256
info@redchip.com
Dave Gentry
RedChip Companies Inc.
1-407-644-4256
info@redchip.com
SOURCE: RedChip
来源：RedChip